Rebamipide-d<sub>4</sub>

Rebamipide-d4

CAT N°: 33543
Price:

293.00 249.05

Rebamipide-d4 is intended for use as an internal standard for the quantification of rebamipide (Item No. 17186) by GC- or LC-MS. Rebamipide is a gastroprotective agent and mucin secretagogue.{61256,61258} It increases the levels of prostaglandin E2 (PGE2; Item No. 14010) and COX-2 in rat gastric mucosa when administered at doses of 15 and 50 mg/kg per day. Rebamipide (30 and 100 mg/kg, i.p.) prevents the formation of gastric ulcers induced by absolute ethanol, sodium hydroxide, or hydrochloric acid in rats, an effect that can be blocked by the non-selective COX inhibitor indomethacin (Item No. 70270).{61257} It also increases the production of mucin 16 in stratified corneal epithelial cells in vitro when used at concentrations of 10 and 100 µM.{61258} Rebamipide (1% w/v) increases the levels of mucin-like substances in rabbit conjunctiva and cornea and, in a rabbit model of dry eye disease, reduces desiccation-induced corneal damage.{61259} Formulations containing rebamipide have been used in the treatment of peptic ulcer disease and dry eye disease.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 2-(4-chlorobenzamido-2,3,5,6-d4)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propanoic acid
  • Correlated keywords
    • deuterated deuterium GCMS LCMS E-2 PGE COX2
  • Product Overview:
    Rebamipide-d4 is intended for use as an internal standard for the quantification of rebamipide (Item No. 17186) by GC- or LC-MS. Rebamipide is a gastroprotective agent and mucin secretagogue.{61256,61258} It increases the levels of prostaglandin E2 (PGE2; Item No. 14010) and COX-2 in rat gastric mucosa when administered at doses of 15 and 50 mg/kg per day. Rebamipide (30 and 100 mg/kg, i.p.) prevents the formation of gastric ulcers induced by absolute ethanol, sodium hydroxide, or hydrochloric acid in rats, an effect that can be blocked by the non-selective COX inhibitor indomethacin (Item No. 70270).{61257} It also increases the production of mucin 16 in stratified corneal epithelial cells in vitro when used at concentrations of 10 and 100 µM.{61258} Rebamipide (1% w/v) increases the levels of mucin-like substances in rabbit conjunctiva and cornea and, in a rabbit model of dry eye disease, reduces desiccation-induced corneal damage.{61259} Formulations containing rebamipide have been used in the treatment of peptic ulcer disease and dry eye disease.

We also advise you